Literature DB >> 27600035

Posaconazole Tablet Formulation at 400 Milligrams Daily Achieves Desired Minimum Serum Concentrations in Adult Patients with a Hematologic Malignancy or Stem Cell Transplant.

Aaron N Pham1, Joseph S Bubalo2, James S Lewis2.   

Abstract

We describe our experience using the posaconazole 400-mg delayed-release tablet formulation once daily in 20 patients with hematologic malignancy or hematopoietic stem cell transplant who were unable to attain prespecified target minimum serum (trough) concentrations for treatment or prophylaxis of invasive fungal infection. The higher dose allowed the majority of patients to achieve prespecified target trough concentrations without incurring additional toxicities.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27600035      PMCID： PMC5075114          DOI： 10.1128/AAC.01489-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  5 in total

Review 1.  Antifungal therapeutic drug monitoring: established and emerging indications.

Authors:  David Andes; Andres Pascual; Oscar Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

2.  Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia.

Authors:  Rafael F Duarte; Javier López-Jiménez; Oliver A Cornely; Michel Laverdiere; David Helfgott; Shariq Haider; Pranatharthi Chandrasekar; Amelia Langston; John Perfect; Lei Ma; Marlou L P S van Iersel; Nancy Connelly; Nicholas Kartsonis; Hetty Waskin
Journal:  Antimicrob Agents Chemother       Date:  2014-07-21       Impact factor: 5.191

3.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Authors:  Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal:  Clin Infect Dis       Date:  2011-02-15       Impact factor: 9.079

4.  Comparison of posaconazole serum concentrations from haematological cancer patients on posaconazole tablet and oral suspension for treatment and prevention of invasive fungal infections.

Authors:  Aaron N Pham; Joseph S Bubalo; James S Lewis
Journal:  Mycoses       Date:  2016-01-06       Impact factor: 4.377

5.  A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers.

Authors:  G Krishna; L Ma; M Martinho; R A Preston; E O'Mara
Journal:  J Antimicrob Chemother       Date:  2012-07-24       Impact factor: 5.790
  5 in total
  5 in total

1.  Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses.

Authors:  Frank P Tverdek; Sang Taek Heo; Samuel L Aitken; Bruno Granwehr; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

2.  Safety study and therapeutic drug monitoring of the oral tablet formulation of posaconazole in patients with haematological malignancies.

Authors:  C Boglione-Kerrien; S Picard; C Tron; S Nimubona; J-P Gangneux; S Lalanne; F Lemaitre; E Bellissant; M-C Verdier; A Petitcollin
Journal:  J Cancer Res Clin Oncol       Date:  2017-09-20       Impact factor: 4.553

Review 3.  New Perspectives on Antimicrobial Agents: Isavuconazole.

Authors:  James S Lewis; Nathan P Wiederhold; Morgan Hakki; George R Thompson
Journal:  Antimicrob Agents Chemother       Date:  2022-08-15       Impact factor: 5.938

4.  Evaluation of Posaconazole Serum Concentrations from Delayed-Release Tablets in Patients at High Risk for Fungal Infections.

Authors:  Alan Chin; Steven A Pergam; David N Fredricks; Andrew N Hoofnagle; Kelsey K Baker; Rupali Jain
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

5.  Comparison of the Efficacy of Posaconazole Delayed Release Tablets and Suspension in Pediatric Hematology/Oncology Patients.

Authors:  Erika N Wass; Elvin A Hernandez; Caroline M Sierra
Journal:  J Pediatr Pharmacol Ther       Date:  2020 Jan-Feb
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.